Angela Mastronuzzi: The necessity to adopt the new classification when considering therapeutic options

Angela Mastronuzzi shared a post on LinkedIn:

“Our recently published paper is out with Frontiers!

Over the last decade, molecular studies have identified an increasing number of key genetic alterations in cancers, and this has improved our knowledge and understanding of the molecular basis underlying tumor biology.

Molecular classification is crucial because many patients are being considered for clinical trials of targeted treatments based on the genetics described on the underlying tumor. Further modification is needed, particularly for rare and poorly characterized tumors.

These important implications for clinical practice highlight the necessity to adopt the new classification when considering therapeutic options (clinical trials, targeted therapies) and discussing prognosis. ”

Read further.
Source: Angela Mastronuzzi/LinkedIn

Angela Mastronuzzi is pediatric hematologist-oncologist and the Head of Neuro-Oncology Unit at Bambino Gesù Children’s Hospital (Italy). She is also a professor at the UniCamillus International Medical University, and a Board Member of AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica). Her main fields of interest are CNS tumors and innovative therapies. She is the author of more than 180 scientific publications in peer-reviewed international journals.